Kentucky Retirement Systems Insurance Trust Fund lifted its holdings in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 0.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 16,416 shares of the medical research company’s stock after acquiring an additional 132 shares during the quarter. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Edwards Lifesciences were worth $2,127,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Jag Capital Management LLC grew its position in Edwards Lifesciences by 21.0% during the 3rd quarter. Jag Capital Management LLC now owns 71,785 shares of the medical research company’s stock valued at $8,127,000 after purchasing an additional 12,435 shares during the last quarter. Stephens Inc. AR grew its position in Edwards Lifesciences by 1.5% during the 3rd quarter. Stephens Inc. AR now owns 26,896 shares of the medical research company’s stock valued at $3,045,000 after purchasing an additional 405 shares during the last quarter. WINTON GROUP Ltd grew its position in Edwards Lifesciences by 398.8% during the 3rd quarter. WINTON GROUP Ltd now owns 14,515 shares of the medical research company’s stock valued at $1,643,000 after purchasing an additional 11,605 shares during the last quarter. Intrua Financial LLC grew its position in Edwards Lifesciences by 11.6% during the 3rd quarter. Intrua Financial LLC now owns 4,077 shares of the medical research company’s stock valued at $473,000 after purchasing an additional 423 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC grew its position in Edwards Lifesciences by 14.2% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 3,695 shares of the medical research company’s stock valued at $418,000 after purchasing an additional 459 shares during the last quarter. 81.91% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE:EW traded down $0.74 during trading on Monday, hitting $119.28. The company’s stock had a trading volume of 1,538,923 shares, compared to its average volume of 2,619,075. The company has a 50-day moving average of $112.55 and a 200-day moving average of $115.09. Edwards Lifesciences Co. has a 12 month low of $87.32 and a 12 month high of $131.73. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.08 and a quick ratio of 2.38. The firm has a market cap of $74.11 billion, a price-to-earnings ratio of 49.91, a P/E/G ratio of 3.36 and a beta of 1.15.
In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,050 shares of the firm’s stock in a transaction that occurred on Friday, April 8th. The shares were sold at an average price of $123.34, for a total transaction of $1,362,907.00. Following the sale, the vice president now owns 152,326 shares in the company, valued at approximately $18,787,888.84. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 20,000 shares of the stock in a transaction that occurred on Monday, April 11th. The shares were sold at an average price of $122.04, for a total transaction of $2,440,800.00. Following the sale, the vice president now directly owns 27,569 shares of the company’s stock, valued at $3,364,520.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 216,859 shares of company stock worth $24,110,684. 1.29% of the stock is owned by company insiders.
Several brokerages recently commented on EW. Truist Financial began coverage on shares of Edwards Lifesciences in a research report on Tuesday, April 12th. They set a “buy” rating and a $145.00 price objective on the stock. Citigroup cut their price objective on shares of Edwards Lifesciences from $142.00 to $138.00 and set a “buy” rating on the stock in a research report on Thursday, January 27th. Credit Suisse Group raised their price target on shares of Edwards Lifesciences from $131.00 to $144.00 and gave the company an “outperform” rating in a report on Friday, January 7th. UBS Group raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price target for the company from $121.00 to $126.00 in a report on Wednesday, February 2nd. Finally, StockNews.com downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday. Five equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $127.52.
About Edwards Lifesciences (Get Rating)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.